Codex DNA, Inc. (DNAY) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET
Company Participants
Todd Nelson - Chief Executive Officer
Brent Hunter - VP of Finance
Conference Call Participants
Brandon Couillard - Jefferies
Operator
Good day, and thank you for standing by. Welcome to the Q2 2022 Codex DNA, Incorporated Earnings Conference Call. [Operator instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Todd Nelson, Chief Executive Officer. Please go ahead.
Todd Nelson
Thank you, Kyle. Good afternoon, and thanks for joining us for Codex DNA's second quarter 2022 earnings call. My name is Todd Nelson, and I'm the CEO here at Codex DNA. With me on the call today are Chief Operating Officer Eric Esser; and our VP of finance, Brent Hunter, who is assuming the responsibilities of our previous CFO, Jennifer McNealey.
Our second quarter press release is available now on the Investors Section of our website. If you'd like to be added to the company's distribution list, please send an email to ir@codexdna.com.
Before we begin, I'd like to inform you that certain statements we make during the call will be forward-looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the safe harbor statement included in our earnings release and in our filings with the SEC. This conference call contains time-sensitive information and is accurate only as of the live broadcast on August 9, 2022. Finally, any percentage changes we discuss will be on a year-over-year basis, unless otherwise noted. And with that, let's get started.
At Codex DNA, our mission is to apply breakthrough automation solutions to global health care and technology markets. Our customers and collaborators include premier academic research institutions, rapidly growing biotech companies and nearly all of the top 25 biopharma companies.
Our systems are utilized by academic and industry sciences worldwide in a variety of discovery activities, ranging from discovering novel infectious disease vaccines to developing precision immunotherapy for cancer and antibody therapeutics, to the creation of engineered meat substitutes and sustainable cellular agricultural products.
Our automation solutions allow scientists to synthesize and assemble DNA and mRNA with the push of a button, allowing us to address large unmet needs within our targeted markets and our customers to bring critical products to the market in an unprecedented amount of time.